FDA Approves Otsuka's Tool SIMTRIYO on July 27, 2026 Approved Attention deficit hyperactivity disorder centanafadine Clinical Nurse Specialists Drug Enforcement Administration NDSRI Otsuka SIMTRIYO Stimulant United States Food and Drug Administration +
Otsuka’s drug eases symptom burden, anxiety in ADHD as FDA verdict nears – 2026 analysis on June 26, 2026 Anxiety Attention deficit hyperactivity disorder centanafadine Otsuka PDUFA United States Food and Drug Administration +
Biopharma Bites: Sarepta's Challenges with DMD Drugs Amid Full Approval Push, DMD Pipeline Advances on March 20, 2026 Amondys Attention deficit hyperactivity disorder Collegium Elevidys Exon Skipping Muscular Dystrophy, Duchenne Vyondys 53 +
Collegium Pharmaceutical Acquires ADHD Drug AZSTARYS from Corium for $650 Million on March 19, 2026 Attention deficit hyperactivity disorder AZSTARYS Collegium Pharmaceutical Dermis drug acquisition milestone payments +